Mitral regurgitation. Summary. Introduction
|
|
- Merilyn Golden
- 7 years ago
- Views:
Transcription
1 Review article: Current opinion Peer reviewed article SWISS MED WKLY 2010;140(3 4): Mitral regurgitation Giovanni B. Pedrazzini, Francesco F. Faletra, Giuseppe Vassalli, Stefanos Demertzis, Tiziano Moccetti Departments of Cardiology and Cardiovascular Surgery, Fondazione Cardiocentro Ticino, Lugano, Switzerland Summary Mitral regurgitation (MR) involves systolic retrograde flow from the left ventricle into the left atrium. While trivial MR is frequent in healthy subjects, moderate to severe MR constitutes the second most prevalent valve disease after aortic valve stenosis. Major causes of severe MR in Western countries include degenerative valve disease (myxomatous disease, flail leaflet, annular calcification) and ischaemic heart disease, while rheumatic disease remains a major cause of MR in developing countries. Chronic MR typically progresses insidiously over many years. Once established, however, severe MR portends a poor prognosis. The severity of MR can be assessed by various techniques, Doppler echocardiography being the most widely used. Mitral valve surgery is the only treatment of proven efficacy.it alleviates clinical symptoms and prevents ventricular dilatation and heart failure (or, at least, it attenuates further progression of these abnormalities). Valve repair significantly improves clinical outcomes compared with valve replacement, reducing mortality by approximately 70%. Reverse LV remodelling after valve repair occurs in half of patients with functional MR. Percutaneous, catheter-based mitral valve repair is a novel approach currently under clinical scrutiny,with encouraging preliminary results. This modality may provide a valuable alternative to mitral valve surgery, especially in critically ill patients. Key words: mitral valve; mitral regurgitation; mitral valve repair; mitral valve replacement; mitral leaflets; heart failure No financial support to declare. Introduction Over four million Europeans and a similar number of Americans suffer from significant mitral regurgitation (MR). Approximately new patients are diagnosed with the disease annually [1, 2]. The disorder generally evolves insidiously over many years because the heart compensates for the regurgitant volume by left atrial enlargement, left ventricular (LV) volume overload, and progressive LV dilatation. Older patients (>50 years) with severe organic MR, defined as an effective regurgitant orifice (ERO) area 40 mm 2, have 6% annual mortality (as compared with 3% for moderate MR) [3]. The most common causes of MR include ischaemic heart disease, nonischaemic heart diseases and valve degeneration. Both ischaemic (coronary artery disease) and nonischaemic heart diseases (e.g., idiopathic dilated cardiomyopathy) cause functional MR via multiple different mechanisms including impaired LV wall motion, LV dilatation, and papillary muscle displacement and dysfunction. In contrast, degenerative ( organic ) MR is caused by structural abnormalities of the valve leaflets and the subvalvular apparatus, including stretching or rupture of tendinous chords (chordae tendineae). Echocardiography plays a central role in the assessment of MR. Valve surgery is the only treatment for which sustained relief from symptoms and prevention (or significant improvement) of heart failure have been demonstrated. However, elderly patients with MR fare less well after valve surgery than those with aortic stenosis. Mortality from mitral valve surgery,especially valve replacement, is increased in older patients or in those with concomitant coronary artery disease. Surgical mortality in the elderly (>75 years) is low in experienced centres but exceeds 20% in less experienced centres [4]. Percutaneous catheter-based mitral valve repair procedures are currently under clinical evaluation. The preliminary results are encouraging [5].
2 SWISS MED WKLY 2010;140(3 4): Figure 1 Anatomical specimen of human mitral valve consisting of the papillary muscles, tendinous chords, and the anterior and posterior leaflet (courtesy of Dr Edgardo Bonacina, Departmant of Pathology, Ospedale Niguarda-Cà Granda, Milano, Italy; reproduced with permission from: Faletra FF. Insufficienza mitralica. Quaderni di ecografia clinica. 2004, vol. 2, ERA Edizioni, Castelseprio VA, Italy). Valve anatomy The mitral valve apparatus consists of the annulus, leaflets and tendinous chords attaching to them, as well as papillary muscles anchoring the chords (fig. 1). The normal mitral valve has two leaflets: anterior and posterior.from an atrial view (fig. 2a), the mitral annulus can be recognised as a roughly elliptical line where the leaflets are anchored to the atrioventricular junction in a D-shaped configuration. The two leaflets are in close contact at the closure line forming a single zone of apposition which determines systolic coaptation between the leaflets (fig. 2b). The two leaflets are divided by two commisures. Small indentations most often partition the posterior leaflet in three scallops (fig. 2c-d); however, four or more scallops also are observed in a minority of patients. The tendinous chords are fibrous stringlike structures attached to the ventricular surface of the leaflets. They are classified as finer marginal (primary) chords and thicker basal (secondary) strut chords [6, 7]. Primary chords position the leaflet tips and prevent prolapse. Secondary chords insert symmetrically near the anterior leaflet base. This classification has implications for mitral valve repair. Unlike the tricuspid valve, the mitral valve does not have chords anchoring the leaflets to the ventricular septum. The papillary muscles are muscular protuberances of the LV wall anchoring the chords to the wall itself. The anterolateral papillary muscle is larger than the posteromedial and is supplied with blood from either the left circumflex or the left anterior descending coronary artery. Because most individuals exhibit a rightdominant pattern of the coronary anatomy, the posteromedial papillary muscle is in most cases supplied with blood from the right coronary artery. Thus, ischaemia in the territory of the left coronary artery frequently affects the anterolateral papillary muscle, whereas ischaemia in the territory of the right coronary artery most often affects the posteromedial papillary muscle. Figure 2 Real-time 3DTEE view of the mitral annulus and leaflets (atrial view); a) Mitral annulus (black arrows); b) Mitral valve; closed position (black arrows: line of coaptation between the two leaflets; asterisks: indentations between scallops). PML =posterior mitral leaflet; AML= anterior mitral leaflet; Ao =aorta; c1) Real-time 3DTEE image of mitral valve in mid-diastole; c2 corresponding anatomical specimen (atrial view). According to Carpentier, scallops of the posterior and anterior leaflets are labelled P1, P2, P3 (from lateral to medial) and A1, A2, A3, respectively (arrows: commissures at the extremities of the coaptation line). Causes and mechanisms of MR Both functional and organic abnormalities causing MR do so by impairing the systolic coaptation between the anterior and posterior leaflet. There are a multiplicity of different causes and mechanisms for MR. A given cause is not invariably linked to the same mechanism; rather, it can affect leaflet coaptation through different mechanisms. Causes of MR can be subdivided into nonischaemic and ischaemic (i.e., related to coronary artery disease). Mechanisms of MR can be subdivided into functional (i.e., MR through a structurally normal valve; e.g., caused by segmental LV wall motion abnormalities, LV dilatation, papillary muscle displacement and dysfunction) and organic (i.e., structural abnormalities of the leaflets or the subvalvular apparatus including the chords). Carpentier introduced a functional classification of MR based on leaflet movement (table 1): Type I with normal leaflet movement (e.g., MR caused by annular dilatation or leaflet perfora-
3 Mitral regurgitation 38 tion); Type II with exaggerated leaflet movement (e.g., mitral valve prolapse); and Type IIIa and IIIb with restricted leaflet movement in diastole and systole, respectively. Ischaemic MR is usually functional in nature and chronic in presentation. Occasionally it is caused by papillary muscle rupture, which is manifested in acute clinical symptoms. After infarction, the papillary muscles are displaced laterally, apically and posteriorly, pulling the leaflet into the left ventricle. Distortion is prominent in the basal anterior leaflet, creating a bend (the seagull sign ) [7]. Papillary muscle dysfunction plays only a minor role compared with apical and inferior papillary muscle displacement caused by ischaemic LV remodelling and dilatation. Because tendinous chords are not extensible, papillary muscle displacement exerts traction on the leaflet, causing tethering, apical leaflet displacement, and impaired coaptation between the two leaflets. Together with annular flattening, enlargement, and reduced contraction, mitral valve tenting affects leaflet coaptation and causes functional MR. Degenerative (organic) MR involves mitral valve prolapse or, less frequently, calcifications of the mitral annulus. Mitral valve prolapse is an abnormal systolic valve movement of one or both of the mitral leaflets towards the left atrium ( 2 mm beyond the saddle-shaped annular plane). Mitral valve prolapse is twice as prevalent in females as in males; however, severe MR caused by prolapse is more frequent in older males than young females. Prolapse is considered to be moderate when the leaflet tip remains in the left ventricle (billowing valve), and severe when the leaflet tip bulges into left atrium (flail leaflet). The latter is usually a consequence of chordal rupture [8]. Structural abnormalities causing mitral prolapse include diffuse myxomatous degeneration and primary flail leaflet with ruptured chords. The latter affects the posterior leaflet in 70% of cases. It can be associated with myxomatous degeneration restricted to the flail portion of the leaflet. Rheumatic MR causes retraction of tendinous chords and leaflets, as well as annular dilatation, thus compromising coaptation between the two leaflets. Similar changes are observed in postinflammatory and postradiotherapy MR. Infectious endocarditis can cause MR through chordal rupture or leaflet perforation. Table 1 Causes and mechanisms of mitral regurgitation. Cause Nonischaemic Mechanism Organic Functional Type I Type II Type IIIa Type I/IIIb Endocarditis (perforation); degenerative (annular calcification); congenital (cleft leaflet) Degenerative (mitral valve prolapse, flail leaflet); endocarditis (ruptured chords) Rheumatic; iatrogenic (radiation/drug); inflammatory (lupus, anticardiolipin); etc. Cardiomyopathy; myocarditis; left ventricular dysfunction (any cause) Ischaemic Ruptured PM Functional ischaemic MR = mitral regurgitation. PM = papillary muscle. Classification according to Carpentier: Type I: normal leaflet movement; Type II: excessive leaflet movement; Type III: restricted leaflet movement (IIIa in diastole, IIIb in systole). Pathophysiology and natural history The regurgitant volume depends upon the regurgitant orifice and the systolic pressure gradient between left ventricle and atrium [9]. Thus, the observed degree of MR depends on haemodynamic conditions at the time of examination. Any increase in preload or afterload, and any decrease in myocardial contractility, causes LV dilatation, enlargement of the mitral annulus, and an increase in ERO. In acute MR the atrium is noncompliant, and therefore mechanical energy generated by the left ventricle causes an increase in intra-atrial pressure. In chronic MR the atrium is more compliant, and therefore mechanical energy generated by the ventricle causes volume overload and atrial enlargement rather than an increase in intraatrial pressure. Consequently,chronic MR may be associated with a small regurgitation wave (the socalled V-wave). Progression of organic MR is associated with an increase in regurgitant volume by 5 7 ml per year.this is manifested by a progressive increase in ERO area due to valvular degeneration and annular enlargement [10]. Patients with chronic MR often remain asymptomatic for many years. Over time, however,the left ventricle dilates to accommodate the increased volume load and maintain cardiac output.chronic LV volume overload leads to contractile dysfunction, heart failure and increased risk of sudden death. Patients with severe, symptomatic MR have a poor prognosis, with a 5% annual mortality if valve surgery is not performed. Progressive heart failure is the most common cause of death in these patients, while sudden death, stroke, and fatal endocarditis are less frequent. Asymptomatic or minimally symptomatic patients with severe MR secondary to mitral valve prolapse and normal LV function at rest have an annual risk of undergoing valve surgery of approximately 10%, mainly due to the appearance of clinical symptoms [11].
4 SWISS MED WKLY 2010;140(3 4): Figure 3 TEE long-axis view showing severe MR due to tethering of the posterior mitral leaflet (functional, ischaemic MR). Assessment of MR Echocardiography plays a central role in the assessment of the mechanism and the severity of MR, as well as of the feasibility of valve repair versus replacement. In severe MR, transthoracic echocardiography (TTE) shows left atrial and ventricular enlargement. LV systolic motion may be increased in the compensatory phase of chronic MR. Peak mitral flow velocity is increased and flow in the pulmonary veins during systole may be reversed. Echocardiography is very useful for identifying the mechanism of MR, e.g., chordal rupture, valve prolapse, rheumatic disease, a flail leaflet, endocarditis or LV dilatation. Calcification of the mitral annulus is visible as a high-density structure between the mitral apparatus and the posterior LV wall. Transoesophageal echocardiography (TEE) is superior to TTE for assessing the precise anatomy of the valve and MR severity. TEE is mandatory when transthoracic images are of suboptimal quality(fig. 3) [12], as well as for pre- and perioperative valve assessment. Real-time three-dimensional (3D) TTE or TEE provides a comprehensive imaging of the mitral valve. 3D TEE images mimic the view of the valve through the left atrium at surgery (fig. 2). This method allows a precise assessment of anatomical structures (e.g., the mitral annulus), which cannot be easily evaluated by 2D modalities. Quantitative methods for assessing the severity of MR include vena contracta and the proximal isovelocity surface area (PISA) method [13]. Vena contracta is defined as the narrowest cross-sectional area of the regurgitant jet determined by colour flow Doppler echocardiography.it correlates well with the severity of MR. The PISA method is based on the acceleration of the regurgitant flow towards the mitral orifice. This flow can be mapped as isovelocity hemispheric shells. ERO area 40 mm 2 and regurgitant volume 60 ml indicate severe MR. These methods have prognostic value. Treatment The impact of different treatments on survival rates has not been evaluated in randomised clinical trials; hence, it can only be estimated from outcome studies [14]. Medical treatment Pharmacological treatment aims to alleviate symptoms and slow down progression of LV dysfunction. In acute MR, nitrates and diuretics reduce filling pressures. Nitroprusside reduces afterload and hence regurgitant fraction. Inotropic agents may be beneficial in patients with heart failure and hypotension. Patients with MR and permanent or paroxysmal atrial fibrillation, and patients with a history of systemic thromboembolism or evidence for a left atrial thrombus should receive anticoagulant therapy with a target international normalised ratio (INR) of 2 3 units [14]. Anticoagulant therapy is also required after mitral valve repair (3 months). In contrast, there is no evidence to support the use of vasodilators, including ACE inhibitors, in chronic MR in the absence of heart failure [15]. Once heart failure is established, however, ACE inhibitors are beneficial. They can be used in patients with advanced MR and severe symptoms who are poor candidates for surgery and in patients who remain symptomatic after surgery due to LV dysfunction. Beta-blocker and spironolactone may also be beneficial in patients with heart failure. According to new guidelines, endocarditis prophylaxis for MR is no longer required; however,it is still mandatory after mitral valve repair (6 months) or mitral valve replacement [16]. Surgical treatment Mitral valve surgery is the only treatment for MR which provides sustained relief of symptoms and prevents the development (or further progression) of heart failure [17]. However, no randomised trials have been carried out to define the precise impact of surgery on mortality and morbidity in these patients. Criteria for mitral valve surgery are summarised in table 2.
5 Mitral regurgitation 40 Mitral valve repair is superior to valve replacement in terms of both mortality and morbidity, and is therefore preferable whenever feasible [17]. This approach includes an array of valvular, subvalvular,and annular procedures aiming to restore leaflet coaptation, i.e., valvular normal function. Overall these techniques are more effective in the presence of redundant, as opposed to retracted or calcified, leaflets. Surgical repair for valve prolapse A typical repair technique for prolapse of a posterior leaflet consists of triangular or quadrangular resection of the prolapsed leaflet segment in conjunction with posterior annulus plication sutures (fig. 4a). Subvalvular support can be achieved by chordal transfer or artificial chords rather than chordal shortening. Annuloplasty is routinely performed by the use of annular bands and either flexible or rigid rings. Prosthetic rings reconstitute and stabilise the correct shape of the annulus and the repaired valve; they therefore represent a mandatory part of mitral valve reconstruction. Surgical repair for anterior leaflet prolapse is more challenging than that for posterior leaflet prolapse. Reconstructive techniques for anterior leaflet prolapse include replacement, shortening or transposition of chords, reinforcement with artificial chords, leaflet-folding plasty and triangular resection [18]. Overall, long-term outcomes of mitral valve repair for anterior leaflet prolapse are satisfactory [18]. Early valve repair of MR caused by leaflet prolapse, before deterioration in LV size or function, increases the likelihood of postoperative normalisation of LV ejection fraction [19]. Table 2 Indications for mitral valve surgery. Class I Symptomatic patient with acute severe MR Chronic severe MR and NYHA functional class II, III or IV symptoms in the absence of severe LV dysfunction (LVEF <30%) and/or ESD >55 mm Asymptomatic patients with chronic severe MR and mild to moderate LV dysfunction, LVEF 30 60%, and/or ESD >40 mm Valve repair is recommended (superior to valve replacement) Class IIa Valve repair is reasonable in experienced surgical centres for asymptomatic patients with chronic severe MR with preserved LV function (LVEF >60% and ESD <40 mm) in whom the likelihood of successful repair without residual MR is >90% (IIb in the guidelines of the European Society of Cardiology) Valve surgery is reasonable for asymptomatic patients with chronic severe MR, preserved LV function, and: New onset of atrial fibrillation Pulmonary hypertension (PASP >50 mm Hg at rest or >60 mm Hg during exercise) Valve surgery is reasonable for patients with chronic severe MR due to primary abnormalities of the mitral apparatus, NYHA functional class III-IV, and severe LV dysfunction (LVEF <30% and/or ESD >55 mm) in whom valve repair is highly likely Class IIb Valve repair can be considered for patients with chronic severe secondary MR due to severe LV dysfunction (LVEF <30%) persistently in NYHA functional class III IV despite optimum therapy for heart failure, including biventricular pacing Class III Valve surgery is not indicated for asymptomatic patients with MR and preserved LV function (LVEF >60% and ESD <40 mm) in whom significant doubt about the feasibility of repair exists Isolated MV surgery is not indicated for patients with mild to moderate MR Abbreviations: ESD: endsystolic diameter; LVEF: left ventricular ejection fraction; PASP: pulmonary artery systolic pressure Figure 4 Left panel: Classical quadrangular resection for mitral valve prolapse. Right panel): New ring design aimed at improving annular support.
6 SWISS MED WKLY 2010;140(3 4): Table 3 In-hospital morbidity and mortality for first time isolated mitral valve surgery (STS 2008). Valve repair for functional MR In functional MR, valve repair rather uniformly includes remodelling of the distorted annulus with a prosthetic ring also aiming to reduce the antero-posterior annular diameter.ring annuloplasty is usually sufficient for nonischaemic functional MR. Surgery for ischaemic functional MR is more demanding. This is mainly due to the sequelae of ischaemic heart disease (regional or diffuse hypo-/ akinesia, ventricular dilatation, ventricular dysfunction) and the tethering of the posterior leaflet usually present due to apical and posterolateral displacement of the papillary muscles following myocardial infarction and ventricular remodelling. The common denominator of all surgical approaches is restrictive (undersized) annuloplasty with a rigid or semirigid ring. Additional procedures specifically address the tethering of the posterior leaflet and include papillary muscle relocation by traction sutures or cutting of second order chordae of the posterior leaflet. So-called saddleshaped annuloplasty rings (e.g., Geoform rings) have recently been developed to address this problem [20]. These rings induce upward traction on the affected papillary muscle towards the mitral annulus. Initial data in patients with ischaemic MR show that mitral valve annuloplasty using the Geoform ring restores leaflet coaptation and eliminates MR by effectively modifying the mitral annular geometry [21]. Centres with wide experience in mitral valve repair report 80 90% success rates [3]. LV reverse remodelling after mitral valve repair was observed in half of patients with functional MR and ischaemic or idiopathic dilated cardiomyopathy [22]. It was associated with longer repair durability and a better clinical outcome than in patients with persistence or progression of the remodelling process. Predictors of reverse remodelling are a preoperative LV enddiastolic diameter <65 mm and a generous coaptation surface between anterior and posterior leaflet after restrictive annuloplasty (coaptation height >8 mm) [23]. Continued LV remodelling contributes to recurrent regurgitation after annuloplasty [24], which is observed in 20 30% of patients after surgical valve repair for postinfarction MR [25]. Careful indication and choice of the surgical procedure, as well as attention to technical details, contribute to improved results [23]. Complication Mitral valve repair Mitral valve replacement Death 1.1% 6.3% Stroke 2.2% 3.8% Renal failure 1.8% 6.9% Prolonged ventilation 9.5% 22.9% Perioperative MI 1.4% 1.7% Reoperation any bleeding other cardiac 5.2% 2.3% 0.8% 11.3% 5.1% 2.2% Valve replacement Valve replacement involves implantation of a biological or mechanical prosthesis. Bioprosthetic valves are associated with lower thromboembolic risk but limited longevity compared with mechanical ones. On the other hand, mechanical valves are associated with increased risk of thrombo-embolism, which mandates chronic anticoagulant therapy,with an associated increased risk of haemorrhagic complications [14, 26]. Considering the theoretical longevity of prosthetic valves, bioprostheses are generally preferred in patients over 65. It is obviously important to discuss the choice of the prosthesis with the patient. Outcome after surgery Clinical outcomes after mitral valve surgery depend on patient- and disease-specific factors, as well as on surgery-related factors. In-hospital morbidity and mortality for first time mitral valve repair and replacement surgery are listed in table 3. Early postoperative mortality is significantly affected by age. However, improvement of surgical techniques in experienced centres has resulted in mortality rates of 1%, 2%, and 4 5% for patients under 65, aged 65 75, and over 75 respectively [27]. Major surgery-related determinants of the operative risk include the surgical procedure used (i.e., valve repair versus replacement) and the need for concomitant CABG surgery [28]. Patients with advanced heart failure generally have a poor prognosis, particularly in the case of functional MR. In a recent study, 5-year survival rates in non-operated patients with ischaemic MR were 38% and 29% in the presence of ERO area < or >20 mm 2 respectively [29]. In a separate highrisk population with post-infarction ischaemic cardiomyopathy treated by surgical ventricular restoration (SVR) and mitral valve repair, 5-year survival was 62% [30]. The effectiveness of SVR, alone or in conjunction with coronary artery bypass grafting (CABG) in patients with ischaemic heart disease and anterior LV dysfunction is under evaluation by the Surgical Treatment for Ischemic Heart Failure (STICH) trial [31]. Management of asymptomatic severe MR The management of asymptomatic patients with severe MR remains controversial. A study in asymptomatic patients with floppy valves reported improved late outcomes after mitral valve repair [32]. On the other hand, a series of 132 consecutive asymptomatic patients (age 55 ± 15 years, 49 female) with severe degenerative MR treated by a watchful waiting approach showed 6% mortality at 5 years [32]. Survival free of any indication for surgery was 92 ± 2% at 2 years, 78 ± 4% at 4 years, 65 ± 5% at 6 years, and 55 ± 6% at 8 years. These data suggest that, in general, asymptomatic patients with severe degenerative MR can be safely followed up until either symptoms occur or currently recommended cutoff values for LV size, LV function, or pulmonary hypertension are
7 Mitral regurgitation 42 Figure 5 Percutaneous mitral clip device (Mitra- Clip System) introduced by venous and transseptal approach into the left atrium and through the mitral orifice. The arms of the clip delivery system are open to grasp the two leaflets following positioning of the device centered over the origin of the regurgitant jet (fig. 6c). reached. However, this management requires careful follow-up. In selected patients with advanced heart failure, Chronic resynchronisation therapy (CRT). attenuates MR, improves cardiac output and alleviates symptoms [34]. Percutaneous, catheter-based mitral valve repair includes leaflet (edge-to-edge) repair and mitral annular reduction. These approaches have not yet been approved for clinical use, but remain largely investigational. Percutaneous edge-to-edge repair mimics the surgical procedure originally proposed by Alfieri [35]. It aims to create a tissue bridge between the anterior and the posterior leaflet by clip deployment via transseptal catheterisation (fig. 5 and 6). Preliminary data are encouraging, with 80% of patients showing mild or trace MR at hospital discharge [36]. Moreover, 12-month follow-up data from the High-Risk Registry Arm of the North American EVEREST II study suggest that highrisk patients with functional or degenerative MR may benefit substantially from mitral clips in terms of morbidity and mortality [37]. Percutaneous mitral annular reduction aims to reduce annular dilatation. This approach generally includes coronary sinus cinching. It has been shown to attenuate MR in animal models [38], but the clinical data are preliminary.achieving a constraining force resulting in >20% diameter reduc- Figure 6 Step-by-step percutaneous edge-to-edge repair (left panel: cartoon provided by the supplier; right panel: real-time 3D TEE); a) guide-wire introduced into the left atrium; b) clip delivery system deployed over the mitral orifice; c) arms of clip delivery system oriented perpendicularly to long axis of leaflet edge; d) clip delivery system anchored to mitral leaflets; e) final result (long axis view). tion is challenging from a technical standpoint. This procedure includes anchoring devices that are placed in the distal and proximal coronary sinus, and an intermediate tensioning or supporting element. A practical limitation is that these devices occupy the space where biventricular pacing leads are frequently positioned for CRT. Conclusions MR imposes volume overload on the left atrium and ventricle, eventually resulting in their progressive dilatation, atrial fibrillation, and heart failure. Pharmacological therapy provides limited symptomatic benefit. Timely mitral valve repair prevents development or further progression of LV dysfunction. Reverse LV remodelling after valve repair occurs in half of patients with functional MR. This approach is the treatment of choice for moderate to severe MR but is not feasible in patients with advanced degenerative abnormalities of the valve. Functional (secondary) MR results from regional LV dysfunction, most often in the context of ischaemic heart disease. Although
8 SWISS MED WKLY 2010;140(3 4): surgical mortality has declined in the past decade, long-term outcomes remain poor. The management of secondary MR includes pharmacological therapy of heart failure and CRT in selected patients. Surgical approaches to secondary MR need to be optimised. Ongoing clinical trials will probably provide new insights into the safety and efficacy of percutaneous mitral valve repair. Correspondence: Giovanni B. Pedrazzini, MD Division of Cardiology Fondazione Cardiocentro Ticino ViaTesserete 48 CH-6900 Lugano, Switzerland References 1 Nkomo VT,Gardin JM, Skelton TN,Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368: Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease. Eur Heart J. 2003;24: Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373: DiGregorio V, Zehr KJ, Orszulak TA, et al. Results of mitral surgery in octogenarians with isolated nonrheumatic mitral regurgitation. Ann Thorac Surg. 2004;78: Feldman T. Percutaneous mitral valve repair. J Interv Cardiol. 2007;20: Kunzelman KS, Cochran RP. Mechanical properties of basal and marginal mitral valve chordae tendineae. ASAIO Trans. 1990;36:M405 M408. 7Messas E, Yosefy C, Chaput M, et al. Chordal cutting does not adversely affect left ventricle contractile function. Circulation. 2006;114:I-524 I Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16: Enriquez-Sarano M, Tribouilloy C. Quantitation of mitral regurgitation: rationale, approach, and interpretation in clinical practice. Heart. 2002;88(Suppl. 4):iv Enriquez-Sarano M, Basmadjian A, Rossi A, Bailey K, Seward J, Tajik A. Progression of mitral regurgitation: a prospective Doppler echocardiographic study. J Am Coll Cardiol. 1999;34: Rosen SE, Borer JS, Hochreiter C, et al. Natural history of the asymptomatic/minimally symptomatic patient with severe mitral regurgitation secondary to mitral valve prolapse and normal right and left ventricular performance. Am J Cardiol. 1994;74: Enriquez-Sarano M, Freeman WK, Tribouilloy CM, et al. Functional anatomy of mitral regurgitation: accuracy and outcome implications of transesophageal echocardiography. J Am Coll Cardiol. 1999;34: Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation N Engl J Med. 2005;352: Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur Heart J. 2007;28: Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008;52: Nishimura, RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118: Shuhaiber J, Anderson RJ. Meta-analysis of clinical outcomes following surgical mitral valve repair or replacement. Eur J Cardiothorac Surg. 2007;31: Morimoto H, Tsuchiya K, Nakajima M, Akashi O. Mitral valve repair for anterior leaflet prolapse: surgical techniques review and 16-year follow-up results. J Card Surg. 2008;23: Suri RM, Scahff HV, Dearanu JA, et al. Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg. 2009;137: Votta E, Maisano F, Bolling SF,Alfieri O, Montevecchi FM, Redaelli A. The Geoform disease-specific annuloplasty system: a finite element study. Ann Thorac Surg. 2007;84: Armen TA, Vandse R, Crestanello JA, Raman SV, Bickle KM, Nathan NS. Mechanisms of valve competency after mitral valve annuloplasty for ischaemic mitral regurgitation using the Geoform ring: insights from three-dimensional echocardiography. Eur J Echocardiogr. 2009;10: De Bonis M, Lapenna E, Verzini a, et al. Recurrence of mitral regurgitation parallels the absence of left ventricular reverse remodeling after mitral repair in advanced dilated cardiomyopathy. Ann Thorac Surg. 2008;85: Braun J, van de Veire NR, Klautz RJM, et al. Restrictive mitral annuloplasty cures ischemic mitral regurgitation and heart failure. Ann Thorac Surg. 2008;85: Hung J, Papakostas L, Tahta SA. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty. Continued LV remodeling as a moving target. Circulation. 2004;110:II-85 II McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg.2004;128: American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-e231 (Erratum in: Circulation. 2007;115:e409). 27 Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral regurgitation in the elderly: outcomes and recent improvements Circulation. 2006;114: Enriquez-Sarano M, Schaff HV, Orszulak TA,Tajik AJ, Bailey KR, Frye RL. Valve repair improves the outcome of surgery for mitral regurgitation. Circulation. 1995;91: Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001;103: Menicanti L, Di Donato M, Frigiola A, et al. Ischemic mitral regurgitation: intraventricular papillary muscle imbrication without mitral ring during left ventricular restoration. J Thorac Cardiovasc Surg. 2002;123: Velazquez EJ,Lee KL, O Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134: David TE, Ivanov J, Armstrong S, Rakowski H. Late outcomes of mitral valve repair for floppy valves: implications for asymptomatic patients. J Thorac Cardiovasc Surg. 2003;125: Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006;113: Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol. 2003;41: Alfieri O, Maisano F, De Bonis M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg. 2001;122: Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: sixmonth results of the EVEREST phase I clinical trial. J Am Coll Cardiol. 2005;46: Kar S. Experience with the MitraClip therapy in the EVER- EST II high-risk registry (abstr). Abstract Book Euro-PCR Byrne MJ, Kaye DM, Mathis M, Reuter DG, Alferness CA, Power JM. Percutaneous mitral annular reduction provides continued benefit in an ovine model of dilated cardiomyopathy. Circulation. 2004;110:
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Mitral Regurgitation Anatomy Mechanisms of MR Presentation Evaluation Management Repair Replace Clip
More informationMitral valve repair current Status and the modern Sternotomy
Mitral valve repair current Status and the modern Sternotomy David L Saint MD, FACS Tallahassee Memorial Hospital Clinical Assistant Professor Florida State University School of Medicine History of Mitral
More informationDurability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease
Keynote Lecture Series Durability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease Tirone E. David Division of Cardiovascular Surgery, Peter Munk Cardiac Centre,
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More information5. Management of rheumatic heart disease
5. Management of rheumatic heart disease The fundamental goal in the long-term management of RHD is to prevent ARF recurrences, and therefore, prevent the progression of RHD, and in many cases allow for
More informationDysfunction of aortic valve prostheses
Dysfunction of aortic valve prostheses Kai Andersen Oslo University Hospital Rikshospitalet, Norway Dysfunction of aortic valve prostheses Kai Andersen Oslo University Hospital Rikshospitalet, Norway No
More informationMitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
More informationSurgical repair of a diseased mitral valve has
Mitral Valve Repair Using the MitraClip: From Concept to Reality Early experience with the MitraClip device suggests that it may be a viable therapeutic option in selected patients with MR. BY SAIBAL KAR,
More informationHeart valve repair and replacement
16 Heart valve repair and replacement 222 Valvular heart disease can be treated in a variety of ways: valve replacement, in which an artificial (prosthetic) heart valve is implanted surgically to replace
More informationReal-Time 3-Dimensional Transesophageal Echocardiography in the Evaluation of Post-Operative Mitral Annuloplasty Ring and Prosthetic Valve Dehiscence
Journal of the American College of Cardiology Vol. 53, No. 17, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.12.059
More informationNikos Kouris a, *, Ignatios Ikonomidis b, Dimitra Kontogianni a, Peter Smith b, Petros Nihoyannopoulos b
Eur J Echocardiography (2005) 6, 435e442 Mitral valve repair versus replacement for isolated non-ischemic mitral regurgitation in patients with preoperative left ventricular dysfunction. A long-term follow-up
More informationMitral regurgitation (MR) arises commonly from
Percutaneous Mitral Valve Repair An overview of the current devices and techniques. BY RAYMOND LEUNG, MDCM, AND TED FELDMAN, MD A Mitral regurgitation (MR) arises commonly from the failure of mitral leaflet
More informationRACE I Rapid Assessment by Cardiac Echo. Intensive Care Training Program Radboud University Medical Centre NIjmegen
RACE I Rapid Assessment by Cardiac Echo Intensive Care Training Program Radboud University Medical Centre NIjmegen RACE Goal-directed study with specific questions Excludes Doppler ultrasound Perform 50
More informationIntroduction. Mitral regurgitation
European Journal of Echocardiography (2010) 11, 307 332 doi:10.1093/ejechocard/jeq031 RECOMMENDATIONS European Association of Echocardiography recommendations for the assessment of valvular regurgitation.
More informationOttavio Alfieri S. Raffaele University Hospital, Milano
The future of mitral surgery: revolution versus involution Ottavio Alfieri S. Raffaele University Hospital, Milano Future The trouble with the future is that it s so much less knowable than the past. John
More informationLow-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
More informationRepair of a regurgitant mitral valve is superior to mitral valve
EDITORIAL ACD GTS ACD ET CSP TX The double-orifice technique in mitral valve repair: A simple solution for complex problems Ottavio Alfieri, MD Francesco Maisano, MD Michele De Bonis, MD Pier Luigi Stefano,
More informationDiagnostic and Therapeutic Procedures
Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationRead It, Code It, See It
Read It, Code It, See It Richard L. Prager, M.D. University of Michigan Ann Arbor, Michigan Dorothy Latham, R.N. Port Huron Hospital Port Huron, Michigan Nothing to Disclose Disclosure Preoperative diagnosis:
More informationThe road to mitral valve repair with live 3D transesophageal echocardiography (TEE)
Clinical applications The road to mitral valve repair with live 3D transesophageal echocardiography (T) R.M. Lang I.S. Salgo A.C. Anyanwu D.H. Adams Professor of Medicine; Director, Noninvasive Cardiac
More informationMinimally Invasive Mitral Valve Surgery
Minimally Invasive Mitral Valve Surgery Stanford Health Care offers leading, superior options in cardiac surgery, including the latest techniques and research for Minimally Invasive Cardiac surgery. Advanced
More informationA bs tr ac t. n engl j med 364;15 nejm.org april 14, 2011 1395
The new england journal of medicine established in 1812 april 14, 2011 vol. 364 no. 15 Percutaneous Repair or Surgery for Mitral Regurgitation Ted Feldman, M.D., Elyse Foster, M.D., Donald D. Glower, M.D.,
More informationChapter 10. Mitral Valve Repair and Redo Repair for Mitral Regurgitation in a Heart Transplant Recipient
Chapter 10 Mitral Valve Repair and Redo Repair for Mitral Regurgitation in a Heart Transplant Recipient Journal of Cardiothoracic Surgery 2012; 7: 100 Wobbe Bouma a Johan Brügemann b Inez J. Wijdh den
More informationPractical class 3 THE HEART
Practical class 3 THE HEART OBJECTIVES By the time you have completed this assignment and any necessary further reading or study you should be able to:- 1. Describe the fibrous pericardium and serous pericardium,
More informationCurrent Strategies of Mitral Valve Repair
Dan Spiegelstein MD, Probal Ghosh MD, Leonid Sternik MD, Salis Tager MD, Amihai Shinfeld MD and Ehud Raanani MD Department of Cardiothoracic Surgery, Sheba Medical Center, Tel Hashomer, Israel Affiliated
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationMedical Policy Manual. Topic: Transcatheter Mitral Valve Repair Date of Origin: November 2015. Section: Surgery Last Reviewed Date: November 2015
Medical Policy Manual Topic: Transcatheter Mitral Valve Repair Date of Origin: November 2015 Section: Surgery Last Reviewed Date: November 2015 Policy No: 199 Effective Date: January 1, 2016 IMPORTANT
More informationRecommendations for Evaluation of the Severity of Native Valvular Regurgitation with Two-dimensional and Doppler Echocardiography
AMERICAN SOCIETY OF ECHOCARDIOGRAPHY REPORT Recommendations for Evaluation of the Severity of Native Valvular Regurgitation with Two-dimensional and Doppler Echocardiography A report from the American
More informationPosterior mitral annuloplasty for enhancing mitral leaflet coaptation: using a strip designed for placement in the posterior annulus
Kim et al. Journal of Cardiothoracic Surgery (2015) 10:164 DOI 10.1186/s13019-015-0350-6 RESEARCH ARTICLE Open Access Posterior mitral annuloplasty for enhancing mitral leaflet coaptation: using a strip
More informationNote: The left and right sides of the heart must pump exactly the same volume of blood when averaged over a period of time
page 1 HEART AS A PUMP A. Functional Anatomy of the Heart 1. Two pumps, arranged in series a. right heart: receives blood from the systemic circulation (via the great veins and vena cava) and pumps blood
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationAdult Cardiac Surgery ICD9 to ICD10 Crosswalks
164.1 Malignant neoplasm of heart C38.0 Malignant neoplasm of heart 164.1 Malignant neoplasm of heart C45.2 Mesothelioma of pericardium 198.89 Secondary malignant neoplasm of other specified sites C79.89
More informationHow should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
More informationCardioband: A New Era of Mitral Valve Repair. Valtech Cardio, Ltd. PCR London Valves. September 22, 2015. Transcript
Cardioband: A New Era of Mitral Valve Repair Valtech Cardio, Ltd. PCR London Valves September 22, 2015 Transcript C O R P O R A T E P A R T I C I P A N T S Prof. Eberhard Grube, M.D., Ph.D., University
More informationPress conference: Rheumatic Heart Disease a forgotten but devastating disease
www.worldcardiocongress.org Chairpersons: Bongani M. Mayosi Jonathan Carapetis Press conference: Rheumatic Heart Disease a forgotten but devastating disease www.worldcardiocongress.org www.worldcardiocongress.org
More informationGERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS
65 G E R I A T R I A 2011; 5: 65-69 GERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS Otrzymano/Submitted: 24.02.2011 Poprawiono/Corrected: 01.03.2011 Zaakceptowano/Accepted: 06.03.2011 Akademia
More informationSection Four: Pulmonary Artery Waveform Interpretation
Section Four: Pulmonary Artery Waveform Interpretation All hemodynamic pressures and waveforms are generated by pressure changes in the heart caused by myocardial contraction (systole) and relaxation/filling
More informationMitral Valve Repair. A. Marc Gillinov and Delos M. Cosgrove
Mitral Valve Repair A. Marc Gillinov and Delos M. Cosgrove Surgical repair of the dysfunctional mitral valve dates back to the early twentieth century when several surgeons developed techniques to try
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationJ of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 42/Oct. 19, 2015 Page 7214
ORGANIC TRICUSPID VALVE REPAIR WITH AUTOLOGOUS GLUTARALDEHYDE FIXED PERICARDIAL PATCH: A SINGLE CENTER RESULTS Murtaza A Chishti 1, Ajay Meena 2, Gaurav Goyal 3, Premraj Nagarwal 4, Varun Chhabra 5, Aashish
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More information5. Diagnosis and management of rheumatic heart disease
5. Diagnosis and management of rheumatic heart disease Introduction Chronic rheumatic valvular heart disease is the long-term result of ARF. It is a disease of poverty and disadvantage. In Australia, the
More informationTranscatheter Mitral Valve Repair
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Transcatheter Mitral Valve Repair Number 2.02.30 Effective Date
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationHow To Treat Aortic Stenosis
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, Society
More informationManagement of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery
Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology
More informationone of the most prevalent cardiac in almost 2.4 percent of the population. 1 Although the incidence of infective
Case Report Hellenic J Cardiol 2011; 52: 177-181 Successful Surgical Repair of Mitral Valve Prolapse Endocarditis: Case Report and Review of the Current Literature Pavlos N. Stougiannos 1, Dimitrios Z.
More informationHISTORY. Questions: 1. What diagnosis is suggested by this history? 2. How do you explain her symptoms during pregnancy?
HISTORY 33-year-old woman. CHIEF COMPLAINT: months duration. Dyspnea, fatigue and nocturnal wheezing of six PRESENT ILLNESS: At ages 5 and 9, she had migratory arthritis. At age 29, in the third trimester
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationGuidelines on the management of valvular heart disease
European Heart Journal doi:10.1093/eurheartj/ehl428 Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology
More informationHeart Murmurs. Outline. Basic Pathophysiology
Heart Murmurs David Leder Outline I. Basic Pathophysiology II. Describing murmurs III. Systolic murmurs IV. Diastolic murmurs V. Continuous murmurs VI. Summary Basic Pathophysiology Murmurs = Math Q =
More informationAutomatic External Defibrillators
Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationContemporary Results of Mitral Valve Repair for Infective Endocarditis
Journal of the American College of Cardiology Vol. 43, No. 3, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.09.034
More informationThe Difficult Mitral Valve Repair in Children, Leave with Stenosis or Regurgitation
The Difficult Mitral Valve Repair in Children, Leave with Stenosis or Regurgitation Abdullah A. Alghamdi, MD, MSc, FRCSC King Abdulaziz Cardiac Center, National Guard Riyadh, Saudi Arabia Outlines Not
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationMitral valve repair versus replacement
Keynote Lecture Series Mitral valve repair versus replacement Stephanie L. Mick, Suresh Keshavamurthy, A. Marc Gillinov Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute,
More informationCriteria for Mitral Regurgitation Classification were inadequate for Dilated Cardiomyopathy
Criteria for Mitral Regurgitation Classification were inadequate for Dilated Cardiomyopathy Frederico José Neves Mancuso 1, Valdir Ambrosio Moisés 1, Dirceu Rodrigues Almeida 1, Wercules Antonio Oliveira
More informationAcute heart failure may be de novo or it may be a decompensation of chronic heart failure.
Management of Acute Left Ventricular Failure Acute left ventricular failure presents as pulmonary oedema due to increased pressure in the pulmonary capillaries. It is important to realise though that left
More information17 Endocarditis. Infective endocarditis
17 Endocarditis 234 Endocarditis refers to inflammation of the endocardium, the inner layer of the heart (including the heart valves). Endocarditis can be: infective (e.g. bacterial, fungal) non-infective
More informationDistance Learning Program Anatomy of the Human Heart/Pig Heart Dissection Middle School/ High School
Distance Learning Program Anatomy of the Human Heart/Pig Heart Dissection Middle School/ High School This guide is for middle and high school students participating in AIMS Anatomy of the Human Heart and
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationMille in Italia e oltre: ABC per il clinico sulle indicazioni e sull implementazione in rete del Sistema MitraClip
Mille in Italia e oltre: ABC per il clinico sulle indicazioni e sull implementazione in rete del Sistema MitraClip Anna Sonia Petronio MD, FESC Head of Cardiac Catheterization Laboratory Cardiothoracic
More informationFlash, Rocking on others Added value in DCM and CRT. C. Parsai Polyclinique des Fleurs France
Flash, Rocking on others Added value in DCM and CRT C. Parsai Polyclinique des Fleurs France Cleland JGF et al. (2007) Nat Clin Pract Cardiovasc Med 4: 90 101 Predicting CRT Response Device Related Patient
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationDevelopment of a surgical simulation toolkit for mitral valve repair surgeries
University of Iowa Iowa Research Online Theses and Dissertations 2014 Development of a surgical simulation toolkit for mitral valve repair surgeries Piyusha Sanjay Gade University of Iowa Copyright 2014
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationAortic Valve Stenosis and CAD
EUROECHO 14, Copenhagen 2010 Aortic Valve Stenosis and CAD Aleksandar N. Neskovic Clinical Hospital Center Zemun Belgrade University School of Medicine Aortic Stenosis and CAD Important facts Links AS/CAD
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationNormal & Abnormal Intracardiac. Lancashire & South Cumbria Cardiac Network
Normal & Abnormal Intracardiac Pressures Lancashire & South Cumbria Cardiac Network Principle Pressures recorded from catheter tip Electrical transducer - wheatstone bridge mechanical to electrical waveform
More informationNational Medicines Information Centre
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006
More informationMitral Valve Insufficiency
Mitral Valve Insufficiency Francesco Fulvio Faletra, Giovanni Pedrazzini, Elena Pasotti and Natesa G. Pandian 2 Mitral valve insufficiency is characterized by the presence of systolic reflow from the left
More informationAnatomi & Fysiologi 060301. The cardiovascular system (chapter 20) The circulation system transports; What the heart can do;
The cardiovascular system consists of; The cardiovascular system (chapter 20) Principles of Anatomy & Physiology 2009 Blood 2 separate pumps (heart) Many blood vessels with varying diameter and elasticity
More informationExchange solutes and water with cells of the body
Chapter 8 Heart and Blood Vessels Three Types of Blood Vessels Transport Blood Arteries Carry blood away from the heart Transport blood under high pressure Capillaries Exchange solutes and water with cells
More informationDiagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses
Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,
More informationHeart Disease: Diagnosis & Treatment
How I Treat Cardiology Peer Reviewed Heart Disease: Diagnosis & Treatment Amara Estrada, DVM, DACVIM (Cardiology) University of Florida Background Clinical heart disease is the stage of disease when a
More informationCurrent concepts for minimally invasive mitral valve repair
Endorsed by proceedings in Intensive Care Cardiovascular Anesthesia Review article HSR Proc Intensive Care Cardiovasc Anesth. In press. Current concepts for minimally invasive mitral valve repair 1 B.
More informationNormal Intracardiac Pressures. Lancashire & South Cumbria Cardiac Network
Normal Intracardiac Pressures Lancashire & South Cumbria Cardiac Network Principle Pressures recorded from catheter tip Electrical transducer - wheatstone bridge mechanical to electrical waveform display
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationMitraClip for the treatment of mitral regurgitation
t h e ne w d e vice MitraClip for the treatment of mitral regurgitation Oliver Gaemperli, Roberto Corti Andreas Gruntzig Laboratories, Cardiovascular Center, University Hospital, Zurich, Switzerland Summary
More informationChallenges in rheumatic valvular disease: Surgical strategies for mitral valve preservation
OPEN ACCESS Research article Challenges in rheumatic valvular disease: Surgical strategies for mitral valve preservation Manuel J Antunes* Center of Cardiothoracic Surgery, University Hospital and Faculty
More information9th Christmas. Echo. International Course on Perioperative and Critical Care. Echocardiography. 19-20 December 2008 Courtyard by Marriott Brussels
9th Christmas Test yourself! Basic course Pre- and Post-course exam Image regognition testing Echo Advanced course Simulated exam for the European Accreditation in Adult Transesophageal Echocardiography
More informationHEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise
WEEK 3 SUPPLEMENT HEART HEALTH A Beginner s Guide to Cardiovascular Disease HEART FAILURE Heart failure can be defined as the failing (insufficiency) of the heart as a mechanical pump due to either acute
More informationCommon types of congenital heart defects
Common types of congenital heart defects Congenital heart defects are abnormalities that develop before birth. They can occur in the heart's chambers, valves or blood vessels. A baby may be born with only
More informationAddendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
More informationCardiac Masses and Tumors
Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:
More informationAortic Stenosis and Comorbidities: the clinical challenge. P. Faggiano Cardiology Division Spedali Civili, Brescia - Italy
Aortic Stenosis and Comorbidities: the clinical challenge P. Faggiano Cardiology Division Spedali Civili, Brescia - Italy 1 Factors affecting decision-making in patients with symptomatic severe aortic
More informationDr Richard Telford. Introduction
Dr Richard Telford Valvular Heart Disease 1. You visit a patient who is due to have an orthopaedic procedure. He tells you he gets occasional chest pain and shortness of breath on exertion. You notice
More informationHow To Understand What You Know
Heart Disorders Glossary ABG (Arterial Blood Gas) Test: A test that measures how much oxygen and carbon dioxide are in the blood. Anemia: A condition in which there are low levels of red blood cells in
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More information2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
More informationMitral Valve Repair: the Multimodal Approach and the Role of Minimally Invasive Procedures
Cardiovascular Surgery SURGICAL TECHNOLOGY INTERNATIONAL IX Mitral Valve Repair: the Multimodal Approach and the Role of Minimally Invasive Procedures GERALD M. LAWRIE, M.D., F.A.C.S. CLINICAL PROFESSOR
More informationLo Scompenso Cardiaco Avanzato: la riparazione transcatetere della valvola mitrale, l assistenza meccanica, e.altro.
Lo Scompenso Cardiaco Avanzato: la riparazione transcatetere della valvola mitrale, l assistenza meccanica, e.altro. Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova
More informationValvular Heart Disease in the Patient Undergoing Noncardiac Surgery
Valvular Heart Disease in the Patient Undergoing Noncardiac Surgery Nancy A. Nussmeier, MD Chair, Department of Anesthesiology SUNY Upstate Medical University, Syracuse, NY Valvular heart disease is becoming
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More information